Lindbrook Capital LLC Acquires 358 Shares of Amgen Inc. (NASDAQ:AMGN)

Lindbrook Capital LLC grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 23.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,906 shares of the medical research company’s stock after purchasing an additional 358 shares during the period. Lindbrook Capital LLC’s holdings in Amgen were worth $549,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of AMGN. Roundview Capital LLC raised its position in shares of Amgen by 1.3% in the first quarter. Roundview Capital LLC now owns 8,383 shares of the medical research company’s stock valued at $2,027,000 after purchasing an additional 107 shares during the period. Merit Financial Group LLC increased its holdings in Amgen by 39.2% during the 1st quarter. Merit Financial Group LLC now owns 2,297 shares of the medical research company’s stock worth $555,000 after acquiring an additional 647 shares during the period. Ergoteles LLC bought a new stake in Amgen during the 1st quarter worth approximately $219,000. First Western Trust Bank bought a new stake in Amgen during the 1st quarter worth approximately $334,000. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in Amgen by 2.1% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 24,688 shares of the medical research company’s stock worth $5,970,000 after acquiring an additional 513 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on AMGN shares. Morgan Stanley decreased their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 7th. UBS Group decreased their target price on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $324.00 to $318.00 in a research note on Wednesday, February 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $329.00 price target on shares of Amgen in a research note on Wednesday, April 3rd. Finally, Oppenheimer reissued an “outperform” rating and issued a $350.00 price target on shares of Amgen in a research note on Thursday, February 1st. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Trading Up 2.4 %

Shares of AMGN opened at $268.93 on Monday. The stock has a market capitalization of $144.25 billion, a P/E ratio of 21.53, a PEG ratio of 2.50 and a beta of 0.58. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The firm has a fifty day simple moving average of $276.90 and a two-hundred day simple moving average of $281.51. Amgen Inc. has a twelve month low of $211.71 and a twelve month high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, beating the consensus estimate of $4.66 by $0.05. The business had revenue of $8.20 billion during the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.09 EPS. On average, research analysts anticipate that Amgen Inc. will post 19.45 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a yield of 3.35%. Amgen’s payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.